PT  - JOURNAL ARTICLE
AU  - Wei-jie Guan
AU  - Wen-hua Liang
AU  - Yi Zhao
AU  - Heng-rui Liang
AU  - Zi-sheng Chen
AU  - Yi-min Li
AU  - Xiao-qing Liu
AU  - Ru-chong Chen
AU  - Chun-li Tang
AU  - Tao Wang
AU  - Chun-quan Ou
AU  - Li Li
AU  - Ping-yan Chen
AU  - Ling Sang
AU  - Wei Wang
AU  - Jian-fu Li
AU  - Cai-chen Li
AU  - Li-min Ou
AU  - Bo Cheng
AU  - Shan Xiong
AU  - Zheng-yi Ni
AU  - Jie Xiang
AU  - Yu Hu
AU  - Lei Liu
AU  - Hong Shan
AU  - Chun-liang Lei
AU  - Yi-xiang Peng
AU  - Li Wei
AU  - Yong Liu
AU  - Ya-hua Hu
AU  - Peng Peng
AU  - Jian-ming Wang
AU  - Ji-yang Liu
AU  - Zhong Chen
AU  - Gang Li
AU  - Zhi-jian Zheng
AU  - Shao-qin Qiu
AU  - Jie Luo
AU  - Chang-jiang Ye
AU  - Shao-yong Zhu
AU  - Lin-ling Cheng
AU  - Feng Ye
AU  - Shi-yue Li
AU  - Jin-ping Zheng
AU  - Nuo-fu Zhang
AU  - Nan-shan Zhong
AU  - Jian-xing He
ED  - ,
TI  - Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis
AID  - 10.1183/13993003.00547-2020
DP  - 2020 May 01
TA  - European Respiratory Journal
PG  - 2000547
VI  - 55
IP  - 5
4099  - http://erj.ersjournals.com/content/55/5/2000547.short
4100  - http://erj.ersjournals.com/content/55/5/2000547.full
SO  - Eur Respir J2020 May 01; 55
AB  - Background The coronavirus disease 2019 (COVID-19) outbreak is evolving rapidly worldwide.Objective To evaluate the risk of serious adverse outcomes in patients with COVID-19 by stratifying the comorbidity status.Methods We analysed data from 1590 laboratory confirmed hospitalised patients from 575 hospitals in 31 provinces/autonomous regions/provincial municipalities across mainland China between 11 December 2019 and 31 January 2020. We analysed the composite end-points, which consisted of admission to an intensive care unit, invasive ventilation or death. The risk of reaching the composite end-points was compared according to the presence and number of comorbidities.Results The mean age was 48.9 years and 686 (42.7%) patients were female. Severe cases accounted for 16.0% of the study population. 131 (8.2%) patients reached the composite end-points. 399 (25.1%) reported having at least one comorbidity. The most prevalent comorbidity was hypertension (16.9%), followed by diabetes (8.2%). 130 (8.2%) patients reported having two or more comorbidities. After adjusting for age and smoking status, COPD (HR (95% CI) 2.681 (1.424–5.048)), diabetes (1.59 (1.03–2.45)), hypertension (1.58 (1.07–2.32)) and malignancy (3.50 (1.60–7.64)) were risk factors of reaching the composite end-points. The hazard ratio (95% CI) was 1.79 (1.16–2.77) among patients with at least one comorbidity and 2.59 (1.61–4.17) among patients with two or more comorbidities.Conclusion Among laboratory confirmed cases of COVID-19, patients with any comorbidity yielded poorer clinical outcomes than those without. A greater number of comorbidities also correlated with poorer clinical outcomes.The presence and number of comorbidities predict clinical outcomes of COVID-19 http://bit.ly/3b9ibw5